A Phase 2 interventional study of Radiopharmaceutical 68Ga-DOTATATE in Neuroblastoma, sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. Recruiting at 3 sites in Canada. Open to participants aged Up to 21 Years. Per ClinicalTrials.gov, last updated 2026-05-27.
Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Phase 2, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 88 studies in Neuroblastoma with a site in Canada — 13 open to participants now, 28 under way, 5 of them phase 3. Neuroblastoma · Canada.
Among the 88 studies in Neuroblastoma with a site in Canada, this one is the 66th largest by planned enrollment of the 78 interventional ones that give a count, is one of 5 that started in 2021, is one of 27 in phase 2, reaches primary completion later than 14 of the 27 other live ones, and was the 78th registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →13 of the 88 studies in Neuroblastoma with a site in Canada are open now. Recruiting first, the newest first:
Renaissance Pharma Ltd. · Sites in Canada, United States, Denmark and 4 more countries
Ages 18 mo–18 yrs
C17 Council · Sites in Canada
Ages up to 6
Milton S. Hershey Medical Center · Sites in Canada, United States
Ages up to 30
Merck Sharp & Dohme LLC · Sites in Canada, United States, Australia and 20 more countries
Ages 6 mo–25 yrs
National Cancer Institute (NCI) · Sites in Canada, United States, Australia and 2 more countries
Ages up to 30
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: Up to 21 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
88 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 34 · Phase 2 40 · Phase 3 15 · Phase 4 1
First in 1988; this study’s year is marked. 5 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 20 is below the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 90 across the 78 interventional studies, 476 across the 8 observational. Of the 52 that completed or were terminated, 29 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 88 have an industry lead sponsor. The 10 most frequent:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke is the lead sponsor of 29 studies on the registry; 10 are open to participants now.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke has 1 study filed under Neuroblastoma — fewer than ten, so there is no comparison to draw.
5 of the studies in Neuroblastoma with a site in Canada that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT02298348New Approaches to Neuroblastoma Therapy ConsortiumSorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma | 2026-12 |
| NCT04901702St. Jude Children's Research HospitalStudy of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma | 2026-12-31 |
| NCT03478462Cellectar Biosciences, Inc.Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas | 2027-06-30 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 88 studies in Neuroblastoma with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Staging of the disease can be done by different imaging strategies (CT, MRI, scintigraphy and PET/CT). Discrepancies may be observed among these different strategies resulting in different treatment strategies. The goal of this study is to assess the feasibility and safety of 68Ga-DOTATATE and to compare it to 123I-MIBG when investigating neuroblastoma.
Background: Neuroblastoma is the most frequent extracranial childhood tumor, with an annual incidence of approximately 10.2 per million children. Initial staging of the disease and monitoring of the treatment response can be performed with different imaging modalities that include contrast-enhanced computed tomography (ceCT), ultrasound, magnetic resonance imaging (MRI), bone scintigraphy and 123I-MIBG scintigraphy.
Another potential target for neuroblastoma imaging is the somatostatin receptor (SSTR) that is present in many neuroendocrine tumours (NET). The superior PET imaging technology used with new radiotracers (such as 68Ga-DOTATATE) enables imaging at advantageous resolutions well below what is possible by current clinical SPECT systems that are used for 123I-MIBG.
Design: Prospective single-arm non-randomized clinical trial (phase II) - pilot
Objective: 1) Assess the feasibility and safety of 68Ga-DOTATATE PET/CT imaging in patients with neuroblastoma or suspected of having neuroblastoma. 2) Compare lesion-by-lesion the uptake of 68Ga-DOTATATE and 123I-MIBG in the same participant.
Study population: Children and adults with biopsy-proven or suspected neuroblastoma
Procedure and Follow-up: Few days after 123I-MIBG scan, participants will undergo a 68Ga-DOTA-cTATE PET/CT scan (duration 2 hours). Clinical data will be collected from this imaging and from the participant's medical record (demographic, treatment, medication, pathology, lab test results) for a 2-year follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all participants will undergo a PET scan with 68Ga-DOTATATE
Biological: Radiopharmaceutical 68Ga-DOTATATE
Injection of 68Ga-DOTATATE followed by PET/CT acquisition
Accrual rate
Number of participants enrolled / year
Time frame: For the duration of the study, lasting 6 years
Rate of adverse events
Number of adverse events (being serious or not) associated to the intervention (injection of 68Ga-DOTATATE and PET/CT acquisition
Time frame: Up to 24 hours following injection of 68Ga-DOTATATE
Positive lesions for 68Ga-DOTATATE
SUV mean of the lesion
Time frame: One hour post-injection of 68Ga-DOTATATE
Discordance of positive lesions for 68Ga-DOTATATE and positive lesions of 123I-MIBG
the number of discordant lesions divided by the number of total positive lesions is the discordance rate
Time frame: Within one week (period between 123I-MIBG scan and 68Ga-DOTATATE scan)
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Dec 2021 (actual). Primary completion is estimated for Dec 2027, 72 months after the start.
Of 62 non-industry phase 2 interventional studies under Neuroblastoma, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 52 and three quarters within 99. This study's planned 72 months is close to that.
Counting every sponsor, half of 67 studies reached it within 74 months; a quarter within 52 and three quarters within 99.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke